Organizations in the life sciences sector faced many difficulties in 2023: a drop-off in fundraising, low market valuation, higher costs for capital expenditures, unstable supply chains, ongoing federal negotiations over drug prices, pharmaceutical shortages, and costs eroding profitabilit